SMC issues latest drug recommendations

The Scottish Medicines Consortium has accepted the following drugs for use within NHS Scotland:

  • atazanavir (Reyataz), co-administered with low dose ritonavir and other antiretrovirals, for HIV in children 6 years of age and older
  • etonogestrel (Nexplanon), for long-acting contraception
  • denosumab (Prolia), for osteoporosis in postmenopausal women at increased risk of fractures. Use is restricted to patients with a bone mineral density T-score < -2.5 and ≥ -4.0 in whom oral bisphosphonates are unsuitable due to contraindication, intolerance or inability to comply with the administration instructions.
  • moxifloxacin infusion (Avelox IV), for the treatment of community acquired pneumonia when other commonly recommended antibacterial agents are inappropriate. Use is restricted to cases where it is recommended by a microbiologist or infectious disease specialist.
  • tacrolimus granules for suspension (Modigraf), to prevent transplant rejection in kidney, liver or heart allograft recipients and to treat allograft rejection resistant to other immunosuppressants. Use is restricted to patients in whom tacrolimus is an appropriate immunosuppressant and who require small dose changes (less than 500 microgram), or who are seriously ill and unable to swallow tacrolimus capsules.

The SMC rejected dexamethasone intravitreal implant (Ozurdex) and prucalopride (Resolor) following full submissions. Gefitinib (Iressa) and ranolazine (Ranexa) were rejected following resubmissions. No submissions were received for fondaparinux sodium (Arixtra) or diclofenac spray (Mobigel).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases